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Cancer is a leading public health crisis facing adults in the United States, with 
estimations that greater than 1.7 million new cancer cases and over 600,000 cancer-related 
deaths will occur in 2018 (1). While the cost of cancer has continued to increase, therapeutic 
advances in the treatment of cancer have grown more specific (2). This specificity has led to 
decreased toxicity, improved patient tolerance, and increased efficacy (3). Radiation and 
chemotherapy are no longer the double-edged swords of the past; fractionated dosage, 
brachytherapy, and 3-D conformational treatments have made radiotherapy more precise and less 
toxic (4). Meanwhile, chemotherapy has undergone its own transformation. The discovery of 
new types of chemotherapy has expanded physicians’ repertoire for dealing with cancer. Along 
with surgery, these treatment modalities have proven to be curative for some malignancies (3). 
Although cancer-associated mortality rates have dropped by 26% over the past two and a 
half decades (1), a large amount of work remains to be accomplished. One avenue that has been 
explored is through the usage of targeted therapy.  Increased understanding of molecular biology 
has presented the opportunity to tailor treatments to patients. Oncologists can now use 
monoclonal antibodies (mAb) to individualize therapies to each malignancy (5). Using mAbs, 
oncogenic pathways in the tumor microenvironment can be targeted. 
         Immunotherapy represents another treatment modality for oncologists. Immunotherapy 
leverages the strength of the immune system to destroy malignant cells. The immune system is 
naturally involved in the defense against cancer. Subsequently, for cancer to progress, it must not 




goal of immunotherapy is to boost the effectiveness of the immune system in order eliminate 
cancer cells. 
The purpose of immune checkpoints is to prohibit an immune response. The aim of 
checkpoint blockade is to promote immune activation by decreasing suppressive signaling (6). 
PD-1 and CTLA-4 were the first two checkpoints targeted. They both have been able to improve 
outcomes in diseases states that were previously hopeless (7). 
Researchers are interested in identifying new checkpoint molecules that could have 
similar positive effects either individually or in combination. PVRIG is one of these molecules. 
This protein is expressed on the cell surface of immune cells. It is structurally similar to TIGIT 
and plays a similar role in regulating immune cell activation (8). PVRIG, TIGIT, and PD-1 
inhibit T-cell activation along the same axis. 
This paper will review the structure and function of PVRIG. It will focus on its novel role 
in the immune system and its potential as an immunotherapy. Recent preclinical data will be 
analyzed, and next steps will be addressed. 
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Cancer has been a part of human existence for centuries. The first recorded instance of 
cancer being described in a medical context was in 1600 BC. The Edwin Smith Papyrus 
describes breast cancer tumors and notes that "there is no treatment (9)." For the next 30 
centuries, knowledge of the human body continued to grow; however, understanding of cancer 
did not (10). Improvements and development of new tools, such as microscopy and x-rays 
respectively, provided the foundation for determining epidemiology of malignancies in humans 
(11,12). The nomenclature used to describe malignancies has evolved over time.  
All cancerous growths were initially characterized as tumors. These tumors were then 
classified primarily based on their tissue of origin. This verbiage is still used today for example: 
breast cancer and colon cancer. Along with the development of the modern microscope, came the 
ability to define cancers by their cell of origin, for example, melanoma and leukemia. Progress in 
molecular biology combined with the invention of new imaging devices led to more precise 
nomenclature. Acute myeloid leukemia with translocation or inversion in chromosome 3 is one 
of over twenty AML diagnoses (13). AML diagnoses are primarily differentiated by genetic 
mutation and/or cell maturation. Breast cancer clinicians have even more specific diagnoses: 
T1N2M0, Stage 2, -/-/-, IIIB (14). Each aspect of the breast cancer diagnosis reflects the 





Early Non-Surgical Treatments 
Radiation 
  
Radiation was discovered in the late 19th century and was recognized as medically 
relevant shortly afterwards. Thanks to the efforts of Marie Curie and her husband, radium 
became a staple of cancer treatment by the dawn of the 20th century. Although radium is no 
longer used in the clinic, the field of radiotherapy has transformed into a critical component of 
cancer care. Along with surgery and chemotherapy, radiation therapy is one of the three major 
treatment modalities for cancer. Radiation therapy is a part of the treatment plan for around half 
of all tumors (15). It is also an extremely efficient method of treatment. While radiotherapy is 
believed to account for approximately 40% of curative treatment, it only costs about 5% of all 
cancer care (15). 
The goal of radiotherapy is to prevent cancer cells from dividing. The ionizing radiation 
that is used damages DNA and prevents cells from proceeding through the cell cycle. Radiation 
affects both cancerous and healthy cells; however, healthy cells are more capable of repairing 
their DNA, meaning malignant cells are relatively sensitive to radiation (16). Radiotherapy is 
divided into two categories based on whether the radiation source is external or internal to the 
patient. Internal radiotherapy, known as brachytherapy, can be temporary, permanent, or 
systemic. External beam therapy, teletherapy, is more common than brachytherapy and accounts 
for nearly 90% of radiotherapy. 
Traditional radiation treatments were limited by toxicity. Clinicians were forced to target 
a large area around the tumor leading to undesired side effects and the inability to treat certain 




Firstly, the standardization of the linear quadratic model for determining radiation effects 
provided radiologists with a more accurate way of estimating fractionation doses (17). Secondly, 
widespread availability of novel imaging devices, including computed tomography scanners and 
magnetic resonance imagers, enabled oncologists to view malignancies in vivo and target tumors 
directly (4). 
Image guided radiation therapy is now incorporated into every form of radiation 
treatment. CT scans and MRI images were quintessential in evolving radiotherapy from 2-D to 
3-D (16). Intensity modulated radiation therapy divides beams in a manner such that malignant 
cells receive the primary dose of radiation, while surrounding blood vessels and other healthy 
tissues are spared (18). Stereotactic radio-surgery relies on precise targeting of an immobile 
target to deliver a one-time lethal dose of radiation. This technique is now used in place of brain 
surgery. By focusing external beams onto a single area, patients can benefit from the killing of 
tumor cells without the cost of invasive surgery (19). Increased understanding of radiobiology, 
along with improvements in the precision of radiotherapy, make radiation an integral part of 




Chemotherapy is a German term that was coined in the early 1900s by Paul Ehrlich. It 
defines a category of chemical agents that are used to treat diseases. While this definition 
encompasses almost all treatments other than radiation or surgery, chemotherapy began to refer 
to cancer treatments in the 1950's (20). It is now specified to be a class of drugs which uses 




The United States started many programs during World War II which led to the 
development of multiple chemotherapy agents that are still used today (3). Gilman and 
Goodman, who had gained experience working with mustard gas exposed soldiers, were tasked 
with finding therapeutic effects for these compounds. They discovered that nitrogen mustard 
caused tumor regression in a mouse model of lymphoma (22). Their findings led to a successful 
clinical trial (23). Their research led to the development of new class of alkylating chemotherapy 
drugs including cyclophosphamide (9). 
Based on research showing that folate deficiency mimics the effects of nitrogen mustard, 
Farber and Kilte used the antifolate drug currently known as methotrexate, to achieve remission 
in children with leukemia (24). Around the same time, Elion and Hitchings developed two drugs 
that affect alanine metabolism. 6-thioquanine and 6-mercaptopurine whose usage in a variety of 
disease settings would earn them the Nobel prize (25). After noticing increased uracil uptake by 
hepatic cancer cells, the Heidelberg lab designed a fluorinated pyrimidine which selectively 
inhibited the growth of malignant liver cells. He was the first person to develop a drug aimed at 
solid cancers, and the first to create a targeted therapy (26). 
Targeted therapy has yielded a silver bullet for the treatment of chronic myeloid 
leukemia. Chronic myeloid leukemia was known to be associated with the Philadelphia 
chromosome. The Philadelphia chromosome is a fusion between chromosomes 9 and 22, 
specifically the genes BCR and ABL proto-oncogene 1 (27). The fusion product created from 
these genes was later found to be a tyrosine kinase. Since this protein was found in 95% of CML 
patients and was believed to be required for transformation, it represented an ideal target for 
therapy (26). Druker at al. was able to develop a compound which displayed sub-uM specificity 




compound exhibited tumor growth inhibition (TGI) in vivo and approximately 95% decrease in 
BCR-ABL1+ colonies in vitro (26). Since the introduction of this drug into the clinic, chronic 
myeloid leukemia five-year survival rates have doubled from 30% to over 60% (28). 
  
Immune Checkpoint Blockade 
  
         Early immunotherapies, such as interleukin-2 (IL-2) and adjuvant focused vaccines, were 
moderately successful. Although these treatments were effective in clearing the initial tumors, 
they were not capable of clearing metastatic cancer or preventing metastases (29). Identification 
of the activation and targeting processes of cytotoxic T lymphocytes (CTLs) by advances in 
immunology provided another pathway for immunologists to control cancer. 
  Researchers, seeking more durable responses, began to focus on CD8 T cells (30). 
Immunologists primarily focused on targeting neoantigens which are only found in the tumor 
microenvironment (31). Initial results indicated that the immune system reacted to antigens 
specific to the patient’s malignancy. In the early 90s, melanoma researchers demonstrated that 
tumor specific CD8 T cells were not recognizing neoantigens. In fact, melanocyte specific 
antigens were the dominant epitopes for the CD8 response to melanoma (31). 
The knowledge and theories of the autoimmunity community became critical for cancer 
immunologists due to the discovery that tumor specific CTLs target self-antigens. The field of 
autoimmunity hypothesizes that the presence of autoantigens is a normal but latent aspect of a 
normal immune system (31).  A dysfunctional autoimmune response to host antigens breaks self-




lymphocyte activation is one way that self-tolerance prevents autoimmunity. Lymphocyte 
activation depends not only on abundance of activation signals, but also on insufficiency of 
inhibitory signals. It is this balance that prevents autoimmune responses and permits activation 
against foreign antigens (33). According to the autoimmune theory, increased density of self-
antigens during an active immune response can expand a previously minuscule population of T 
cells sufficiently to initiate an autoimmune response (31). 
Since a population of cells exist that can target malignant cells and expand in response to 
increasing tumor burden, the intention changes from initiating an immune response, to increasing 
the initial response. The initial response is against a self-antigen, a conventionally inhibited 
reaction; therefore, the goal is to induce an autoimmune response by suppressing its inhibition 
(31). 
  
Programmed Death 1 (PD-1) 
  
         PD-1 was initially discovered in 1992 while searching for genes related to apoptosis (34). 
This group noted an autoimmune phenotype in PD-1 knockout mice. Further studies revealed 
that autoreactive PD-1 deficient mice suffered from splenomegaly and graft versus host disease. 
Honjo et al. interpreted their findings to indicate that PD-1 was a negative regulator of the 
immune system.  Around the same time, Lieping Chen’s group discovered a ligand to an 
unknown receptor and labeled it B7 homolog 1 (B7-H1) (35). Pardoll and colleagues discovered 
another B7 family ligand believed to be dendritic cell (DC) restricted, which they named B7-DC 
(36). Shortly afterwards, Gordon Freeman and colleagues identified that both B7 ligands bound 




         PD-1 is a monomeric cell surface protein which contains one variable immunoglobulin 
(vIG)-like domain in the extracellular portion. Although the extracellular IgE domain shares 25% 
similarity to cytotoxic T-lymphocyte antigen 4 (CTLA-4), the intracellular domain of PD-1 
contains different signaling sequences (40). PD-1 exhibits its downstream effects through an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based 
switch motif (ITSM).  Upon ligation of the T cell receptor (TCR) or the B cell receptor (BCR), 
these motifs recruit phosphatases resulting in inhibition of receptor and local costimulatory 
signals (38). 
         PD-1 expression is increased on tumor infiltrating lymphocytes (TILs) who exhibit 
decreased killing ability. Tumor cells often overexpress PD-L1 as well (41). Engagement of PD-
L1 on tumor cells by PD-1 on TILs provides survival signals for the malignancy, while 
simultaneously inhibiting T cell activation. For these reasons, blockade of PD-1 signaling was 
viewed as an ideal target (42). 
         The results of PD-1 blockade in the initial clinical trials were so positive that larger 
multi-center trials began immediately (43). These treatments have increased overall survival 
rates and progression-free survival in patients with advanced metastatic malignancies. 
Importantly, some patients with ongoing disease were able to stabilize and survive after 
discontinuing treatment (44). The success of PD-1 blockade as monotherapy has led to an 








T cell Immunoglobulin and ITIM domain (TIGIT) 
  
           Three groups identified different aspects of the same protein in 2009. Grogan and 
colleagues named the protein TIGIT and recognized that poliovirus receptor (PVR) was one of 
its ligands (45). They also identified poliovirus receptor-like ligand 2 (PVRL2) as a second, low 
affinity ligand for TIGIT.  In their paper, they describe TIGIT as indirectly suppressing T-cell 
activation through DCs. The Mandelboim group showed that TIGIT directly inhibits natural 
killer (NK) cell killing (46). Marco Colonna and colleagues revealed high expression of TIGIT 
on follicular CD4 T cells and PVR on follicular DCs. Taken together, they hypothesized a role 
for TIGIT in germinal center interactions (47). 
         TIGIT is a member of the nectin/nectin-like binding receptor family, which includes 
DNAX accessory molecule 1 (DNAM-1) and poliovirus receptor-like immunoglobulin domain 
containing (PVRIG). It contains one extracellular immunoglobulin domain as well as a single 
intracellular ITIM. TIGIT functions on the cell surface as a homodimer and has high basal 
expression on regulatory T cells and NK cells (48). Activation of CD4 and CD8 T cells leads to 
its upregulation, promoting its inhibitory functions (49). TIGIT inhibition in cis is mediated by 
interrupting DNAM-1 dimerization, thereby preventing DNAM-1 from sending activation 
signals (50). Additionally, TIGIT competes with DNAM-1 for the ligand PVR. TIGIT 
engagement on activated T cells suppresses TCR and CD28 signaling pathways by 
downregulating proteins that make up the TCR complex (48). On NK cells, TIGIT’s ITT motif 





         TIGIT is an attractive target for cancer immunologists because its blockade can increase 
activation and inhibit suppression (52). TIGIT blockade can preclude suppression by preventing 
the induction of immunosuppressive DCs and subsequent skewing of T cells from cytotoxic to 
inflammatory. In the tumor microenvironment, TIGIT blockade can directly promote malignant 
cell killing by both NK cells and CD8 T cells; additionally, it can stifle immunosuppressive 
signals from regulatory T cells (53). These factors have led to a surge in publications and clinical 




         PVRIG is a newly discovered nectin/nectin-like receptor. Ben Koop and colleagues 
discovered the gene analyzing the PILR locus. It was named due to sharing variable 
immunoglobulin domain with poliovirus receptor-like genes (55).  Another 10 years passed 
before researchers would determine its role. In 2016, Zhu et al. characterized the structure and 
binding partner for PVRIG (56). 
PVRIG is a monomeric cell surface protein with one vIg domain and an ITIM-like motif 
on the intracellular domain. NK cells and CD8 T cells express the protein at rest, while 
stimulation induces expression on CD4 T cells and upregulates expression on NK and CD8 T 
cells (57). Zhu and colleagues demonstrated that PVRL2 is the primary ligand mediating PVRIG 
interactions between T cells and DCs or tumor cells. Results from their competitive binding 
assay show that PVRIG has a higher affinity for PVRL2 than TIGIT or DNAM-1.  Blockade of 
PVRIG increases T cell proliferation and cytokine production by CD4 T cells and NK cells. 




findings suggest that co-blockade of PVRIG synergistically enhance T cell function in a manner 




























         PVRIG is a novel immunomodulatory receptor. At the time of this writing, a search of 
Pubmed returns only four results. As indicated by the paucity of publications, there are still many 
questions to be answered regarding its role in both healthy and diseased states. In collaboration 
with Compugen, the Pardoll lab has investigated the influence of PVRIG in cancer models, with 
the goal of translating pre-clinical findings into improved patient outcomes. 
         PVRIG and TIGIT co-blockade represents a multi-faceted approach to promote TIL 
activation through DNAM-1. High affinity bindings of PVRIG to PVRL2 and TIGIT to PVR, 
prevent DNAM-1 ligation. (Figure 1). Blocking these two inhibitory receptors not only increases 
available ligands for DNAM-1, it also abrogates their intracellular suppressive signaling. 
  
The Role of PVRIG in Cancer Immunology 
  
Using flow cytometry as a readout, Pardoll et al. demonstrate that there is no 
promiscuous binding of PVRIG to PVR or TIGIT to PVRL2 on Expi293 cells (Figure 2A). The 
same effect is shown by interferon-gamma (IFNγ) production from donor T cells. Blockade of 
both PVRIG and TIGIT pathways enhances IFNγ production to 2000 pg/mL; however, blockade 
of either pathway alone results in approximately 1500 pg/mL increase of IFNγ. 
Functionally, co-blockade leads to a significant reduction in tumor growth (Figure 3). 
TGI is highest in TIGIT KO mice treated with anti-mPVRIG. PVRIG is known to be expressed 




cancer patient samples (Figure 4). The data from figure 5 displays percentage of exhausted CD8 
T cells, subsets are based on the expression of PD-1, PVRIG, and TIGIT. PVRIG is most highly 
correlated with exhausted CD8 T cells (Rows 1-4), the largest percentage of which is shared with 
PD-1 and TIGIT respectively. These results are supported by the TGI and survival of mice in 
their CT26 syngeneic model. Combining anti-mPD-L1 and anti-mPVRIG treatments 
significantly decreases tumor size and increases overall survival (Figure 6). 
  
Pre-Clinical Studies of Novel PVRIG Blocking Antibody COM701 
  
Data gathered from mouse models and patient samples warranted the development of a 
human blocking antibody for PVRIG. A new treatment model was also devised, which includes 
blockade of the three checkpoints discussed earlier (Figure 7). Preliminary testing demonstrates 
that COM701 increases CD4 T cell proliferation and CD8 T cell cytotoxicity; this cytotoxic 
activity was further enhanced by blocking TIGIT (Fig 8). Synergistic effects were noted in the 
tri-blockade of COM701, anti-PD-1, and anti-TIGIT. IFNγ production is modestly increased by 
single blockade, co-blockade strengthens this effect further, and tri-blockade results in over 
300% increase from control (Fig 9).  
After confirming COM701 efficacy on healthy cells, the Pardoll lab examined 
COM701’s effects on tumor derived cells. Ex vivo experiments on TILs from cancers of the 
kidney, endometrium, and ovary were analyzed for signs of activation. TILs were treated with 
COM701, COM902 (anti-TIGIT), or Pembrolizumab (anti-PD-1). Single agent treatment 
moderately increases IFNγ levels; however, co-blockade with COM701 and COM902 most 




in lung cancer. IFNγ, tumor necrosis factor alpha, and IL-2 displayed higher increases with co-




























PD-1 therapy has become the standard of care for some malignancies; unfortunately, not 
all patients respond to this treatment, and not all responders achieve durable remission. 
Combination therapy is believed to be one method for advancing the success of checkpoint 
blockade (60). CTLA-4 has been used in conjunction with PD-1 and has improved patient 
outcomes; however, this progress has come at the cost of intensifying immune-related adverse 
effects (irAE) (61). These irAEs prevent patients from being able to continue therapy and can be 
lethal. Although the benefits outweigh the risks, there is a desire for additional options for 
combination checkpoint blockade. 
Pardoll and colleagues provide another actionable target for checkpoint blockade. PVRIG 
is a novel inhibitory receptor. Co-blockade of PVRIG + TIGIT or PVRIG + PD-L1 inhibits 
tumor growth in B16gp100 and CT26 models respectively (Fig 3, 6). In vitro tri-blockade of PD-
1, PVRIG, and TIGIT maximally enhances T cell IFNγ production. Blockade with COM701 
alone and especially in combination with Pembrolizumab or COM902 blocking antibodies has 
also been shown to enhance activation of patient TILs from endometrial, ovarian, and lung 
cancers (Fig 10,11). 
PVRL2 expression in tumors further enhances the viability of COM701 as a novel 
immunotherapy. PVRL2 maintains a similar expression profile in tumors regardless of PD-L1 
status, meaning that COM701 can be indicated for a specific cancer even if the tumor is PD-L1- 




important aspect for combining with PD-1 blockade since the relatively low toxicity of anti-PD-1 
therapy is believed to be due to its primarily tumor induced function (62). For this reason, 
COM701 co-blockade is expected to have less irAE than CTLA-4 co-blockade. The body of 
work produced by Pardoll and colleagues on PVRIG has successfully cleared COM701 for phase 
1 clinical trials (63). 
Next steps for COM701 will involve translating data from the bedside to the bench. The 
mechanisms behind clinical responses will need to be elucidated and a predictive algorithm for 
patient response will have to be designed. Identification of a soluble biomarker from blood 
samples would be ideal, as it can be used to predict and track patient responses. Tumor samples 
should be used to examine immune infiltrate and changes in protein expression throughout 
treatment. Finally, phenotyping of TILs will provide information on their activation status and 






























Figure 2: A-Left) Binding of PVRIG/TIGIT with increasing concentration of anti-PVR/PVRL2 
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